Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTTR1147A versus placebo and vedolizumab in moderate to severe ulcerative colitis
NL-OMON46667Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Apr 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efmarodocokin alfa and vedolizumab in autoimmune colitis (8 arms), sponsored by Roche. Planned start Apr 2018; status: withdrawn.
02
Drugs
efmarodocokin alfavedolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON46667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46667.